168 related articles for article (PubMed ID: 33332018)
1. Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England.
Rothwell B; Kiff C; Ling C; Brodtkorb TH
Pharmacoecon Open; 2021 Jun; 5(2):251-260. PubMed ID: 33332018
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of nivolumab in squamous and non-squamous non-small cell lung cancer in Canada and Sweden: an update with 5-year data.
Chaudhary MA; Holmberg C; Lakhdari K; Smare C; Theriou C; Dale P; Penrod JR
J Med Econ; 2021; 24(1):607-619. PubMed ID: 33870833
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
5. Cost Effectiveness of Durvalumab in Unresectable Stage III NSCLC: 4-Year Survival Update and Model Validation from a UK Healthcare Perspective.
Dunlop W; van Keep M; Elroy P; Perez ID; Ouwens MJNM; Sarbajna T; Zhang Y; Greystoke A
Pharmacoecon Open; 2022 Mar; 6(2):241-252. PubMed ID: 34532842
[TBL] [Abstract][Full Text] [Related]
6. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer.
Greenhalgh J; McLeod C; Bagust A; Boland A; Fleeman N; Dundar Y; Oyee J; Dickson R; Davis H; Green J; McKenna E; Pearson M
Health Technol Assess; 2010 Oct; 14(Suppl. 2):33-9. PubMed ID: 21047489
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes.
Goeree R; Villeneuve J; Goeree J; Penrod JR; Orsini L; Tahami Monfared AA
J Med Econ; 2016 Jun; 19(6):630-44. PubMed ID: 26850122
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of atezolizumab versus docetaxel and nivolumab in the treatment of non-small cell lung cancer as a second line in France.
Marine S; Stéphane R; Nicolas P; Felizzi F; Paracha N; Benjamin M; Perol M
J Med Econ; 2020 May; 23(5):464-473. PubMed ID: 31951770
[No Abstract] [Full Text] [Related]
9. Cost-effectiveness of nivolumab in patients with NSCLC in the United States.
Chaudhary MA; Lubinga SJ; Smare C; Hertel N; Penrod JR
Am J Manag Care; 2021 Aug; 27(8):e254-e260. PubMed ID: 34460179
[TBL] [Abstract][Full Text] [Related]
10. Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models.
Gao L; Li SC
Appl Health Econ Health Policy; 2019 Jun; 17(3):371-380. PubMed ID: 30535675
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Morgan P; Woolacott N; Biswas M; Mebrahtu T; Harden M; Hodgson R
Pharmacoeconomics; 2017 Sep; 35(9):909-919. PubMed ID: 28342113
[TBL] [Abstract][Full Text] [Related]
12. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
Matter-Walstra K; Schwenkglenks M; Aebi S; Dedes K; Diebold J; Pietrini M; Klingbiel D; von Moos R; Gautschi O;
J Thorac Oncol; 2016 Nov; 11(11):1846-1855. PubMed ID: 27311996
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
Zargar M; McFarlane T; Chan KKW; Wong WWL
Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China.
Zhou D; Luo X; Zhou Z; Zeng X; Wan X; Tan C; Liu Q
Front Pharmacol; 2022; 13():880280. PubMed ID: 36091746
[No Abstract] [Full Text] [Related]
15. Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States.
Huang M; Lou Y; Pellissier J; Burke T; Liu FX; Xu R; Velcheti V
J Med Econ; 2017 Feb; 20(2):140-150. PubMed ID: 27571538
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
Hirschmann A; Lupatsch JE; Schwenkglenks M; Panje CM; Matter-Walstra K; Espeli V; Dedes KJ; Siano M;
Oral Oncol; 2018 Dec; 87():104-110. PubMed ID: 30527224
[TBL] [Abstract][Full Text] [Related]
17. First-line nivolumab plus ipilimumab or chemotherapy
Cao X; Cai H; Li N; Zheng B; Zheng Z; Liu M
Ther Adv Med Oncol; 2022; 14():17588359221122733. PubMed ID: 36147862
[TBL] [Abstract][Full Text] [Related]
18. Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Kearns B; Pandor A; Stevenson M; Hamilton J; Chambers D; Clowes M; Graham J; Kumar MS
Pharmacoeconomics; 2017 Apr; 35(4):415-424. PubMed ID: 27770303
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Nivolumab Plus Ipilimumab as First-Line Therapy in Advanced Non-small-cell Lung Cancer.
Hao X; Shen A; Wu B
Front Pharmacol; 2021; 12():573852. PubMed ID: 34290602
[No Abstract] [Full Text] [Related]
20. Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer.
Wan X; Zeng X; Peng L; Peng Y; Liu Q; Yi L; Luo X; Deng Q; Tan C
Front Pharmacol; 2021; 12():580459. PubMed ID: 34512315
[No Abstract] [Full Text] [Related]
[Next] [New Search]
